Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-γ receptor treatment

Brain, Behavior, and Immunity

Volumn 12, Issue 2, 1998, Pages 90-106

  Schrott, Lisa M ^a   Crnic, Linda S ^a  

^a NONE

Author keywords

Activity; Anxiety; Cytokines; Elevated plus maze; Exploration; Psychoneuroimmunology; Systemic lupus erythematosus

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; BEHAVIOR DISORDER; CONTROLLED STUDY; DISEASE COURSE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031818233     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1006/brbi.1998.0522     Document Type: Article

References (59)

1. 1. Clin. Exp. Immunol. 40:1980;373-382.
2. Bresnihan B., Hohmeister R., Cutting J., Travers R. L., Waldburger M., Black C., Jones T., Hughes G. R. V. The neuropsychiatric disorders in systemic lupus erythematosus: Evidence for both vascular and immune mechanisms. Ann. Rheum. Dis. 38:1979;301-306.
3. Crnic L. S., Segall M. A. Behavioral effects of mouse interferons-α and -γ and human interferon-α in mice. Brain Res. 590:1992;277-284.
4. Cruz A. P. M., Frei F., Graeff F. G. Ethopharmacological analysis of rat behavior on the elevated plus maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
5. Dantzer R., Bluthé R. M., Kent S., Goodall G. Behavioral effects of cytokines: An insight into mechanisms of sickness behavior. Neurobiology of cytokines. 1993;Academic Press, San Diego. p. 130-150.
6. Denburg S. D., Carbotte R. M., Long A. A., Denburg J. A. Neuropsychological correlates of serum lymphocytoxic antibodies in systemic lupus erythematosus. Brain Behav. Immun. 2:1988;222-234.
7. Denburg J. A., Carbotte R. M., Denburg S. D. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology. 37:1987;464-467.
8. Denburg J. A., Temesvari P. The pathogenesis of neuropsychiatric lupus. Can. Med. Assoc. J. 128:1983;257-260.
9. Dixon F. J. Murine lupus - An overview. Arth. Rheum. 25:1982;721-725.
10. Dunn A. J. Role of cytokines in infection-induced stress. Ann. N.Y. Acad. Sci. 697:1993;189-202.
11. Dunn A. J., Berridge C. W. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
12. 1Mycobacterium bovis. Arth. Rheum. 24:1981;1396-1402.
13. Feldmann M., Londei M., Buchan G. Interferons and autoimmunity. Interferon. 9:1987;75-90.
14. Ferrell P. B., Tan E. M. Systemic lupus erythematosus. Rose N. R., Mackay J. R. The autoimmune diseases. 1985;29-57 Academic Press, San Diego.
15. File S. E. The interplay of learning and anxiety in the elevated plus maze. Behav. Brain. Res. 58:1993;199-202.
16. Fountoulakis M., Schlaeger E.-J., Gentz R., Juranville J.-F., Manneberg M., Ozmen L., Garotta G. Purification and biochemical characterization of a soluble mouse interferon-γ receptor produced in insect cells. Eur. J. Biochem. 198:1991;441-450.
17. Gentz R., Hayes A., Grau N., Fountoulakis M., Ozmen L., Garotta G. Analysis of soluble human and mouse interferon-γ receptors expressed as eukaryotic cells. Eur. J. Biochem. 210:1993;545-554.
18. Glass D., Schur P. H. Autoimmunity and systemic lupus erythematosus. Talal N. Autoimmunity. Genetic, immunologic, virologic and clinical aspects. 1977;531-568 Academic Press, San Diego.
19. Handwerger B. S., Rus V., da Silva L., Via C. S. The role of cytokines in the immunopathogenesis of lupus. Semin. Immunopathol. 16:1994;153-180.
20. Hanly J. G., Walsh N. M., Fisk J. D., Eastwood B., Hong C., Sherwood G., Jones J. V., Jones E., Elkon K. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Brit. J. Rheumatol. 32:1993;291-296.
21. Hart B. L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12:1988;123-137.
22. Heinrichs S. C., Menzaghi F., Pich E. M., Baldwin H. A., Rassnick S., Britton K. T., Koob G. F. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology. 11:1994;179-186.
23. Heremans H., Billiau A., Colombatti A., Hilgers J., De Somer P. Interferon treatment of NZB mice: Accelerated progression of autoimmune disease. Infect. Immun. 21:1978;925-930.
24. Horwitz D. A., Jacob C. O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Semin. Immunopathol. 16:1994;181-200.
25. Iverson G. L. Psychopathology associated with systemic lupus erythematosus: A methodological review. Semin. Arth. Rheum. 22:1993;242-251.
26. Jacob C. O., van der Meide P. H., McDevitt H. O. In vivo. J. Exp. Med. 166:1987;798-803.
27. Lee C., Rodgers R. J. Antinocioceptive effects of elevated plus-maze exposure: Influence of opiate receptor manipulations. Psychopharmacology. 102:1990;507-513.
28. Lim L., Ron M. A., Ormerod I. E. C., David J., Miller D. H., Logsdail S. J., Walport M. J., Harding A. E. Psychiatric and neurological manifestation in systemic lupus erythematosus. Q. J. Med. 66:1988;27-38.
29. Lister R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
30. Lister R. G. Interactions of three benzodiazepine receptor inverse agonists with ethanol in a plus-maze test of anxiety. Pharmacol. Biochem. Behav. 30:1988;701-706.
31. Ossenkopp K.-P., Mazmanian D. S. The measurement and integration of behavioral variables: Aggregation and complexity as important issues. Neurobehav. Toxicol. Teratol. 7:1985;95-100.
32. Ozmen L., Gribaudo G., Fountoulakis M., Gentz R., Landolfo S., Garotta G. Mouse soluble interferon-γ receptor as IFN-γ inhibitor. Distribution, antigenicity, and activity after injection in mice. J. Immunol. 150:1993;2698-2705.
33. Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., Garotta G. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:1995;6-12.
34. Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., Garotta G. Soluble interferon-γ receptor: A therapeutically useful drug for systemic lupus erythematosus. J. Interf. Res. 14:1994;283-284.
35. Plata-Salamán C. R., Borkoski J. P. Chemokines/intercrines and central regulation of feeding. Amer. J. Physiol. 266:1994;R1711-R1715.
36. Reichlin M. Systemic lupus erythematosus. Bigazi P. E., Reichlin M. Systemic Autoimmunity. 1991;163-199 Dekker, New York.
37. Rodgers R. J., Lee C., Shepherd J. K. Effects of diazepam on behavioral and antinocioceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology. 106:1992;102-110.
38. Sakic B., Denburg J. A., Denburg S. D., Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: A curve-shift study. Brain Res. Bull. 41:1996;305-311.
39. Sakic B., Szechtman H., Braciak T., Richards C., Gauldie J., Denburg J. A. Reduced preference for sucrose in autoimmune mice: A possible role of interleukin-6. Brain Res. Bull. 44:1997;155-165.
40. Sakic B., Szechtman H., Denburg J. A. Neurobehavioral alterations in autoimmune mice. Neurosci. Biobehav Rev. 21:1997;327-340.
41. Sakic B., Szechtman H., Denburg S. D., Carbotte R., Denburg J. A. Brain-reactive antibodies and behavior of autoimmune MRL-lpr mice. Physiol. Behav. 54:1993;1025-1029.
42. Sakic B., Szechtman H., Denburg S. D., Denburg J. A. Immunosuppressive treatment prevents behavioral deficit in autoimmune MRL-lpr mice. Physiol. Behav. 58:1995;797-802.
43. Sakic B., Szechtman H., Keffer M., Talangbayan H., Stead R., Denburg J. A. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav. Immun. 6:1992;265-285.
44. Sakic B., Szechtman H., Talangbayan H., Denburg S. D., Carbotte R., Denburg J. A. Disturbed emotionality in autoimmune MRL-lpr mice. Physiol. Behav. 56:1994;609-617.
45. Schattner A. Lymphokines in autoimmunity - A critical review. Clin. Immunol. Immunopathol. 70:1994;177-189.
46. Schattner A. Interferons and autoimmunity. Am. J. Med. Sci. 295:1988;532-544.
47. Schrott L. M., Crnic L. S. Sensitivity to footshock in autoimmune NZB × NZW F1 hybrid mice. Physiol. Behav. 56:1995;849-853.
48. Schrott L. M., Crnic L. S. Increased anxiety behaviors in autoimmune mice. Behav. Neurosci. 110:1996a;492-502.
49. Schrott L. M., Crnic L. S. Anxiety behavior, exploratory behavior, and activity in NZB × NZW F1 hybrid mice: Role of genotype and autoimmune disease progression. Brain Behav. Immun. 10:1996b;260-274.
50. Schrott L. M., Crnic L. S. The role of performance factors in the active avoidance conditioning deficit in autoimmune mice. Behav. Neurosci. 110:1996c;486-491.
51. Sergiescu D., Cerutti I., Efthymiou E., Kahan A., Chany C. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine. 31:1979;48-51.
52. Sergiescu D., Cerutti I., Kahan A., Piatier D., Efthymiou E. Isoprinosine delays the early appearance of autoimmunity in NZB/NZW F1 mice treated with interferon. Clin. Exp. Immunol. 43:1981;36-45.
53. Steinberg A. D., Baron S., Talal N. The pathogenesis of autoimmunity in New Zealand mice. I. Induction of anti-nucleic acid antibodies by polyinosine-polycytidylic acid. Proc. Natl. Acad. Sci. USA. 63:1969;1102-1107.
54. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Tallal N., Winchester R. J. The 1982 revised revised criteria for the classification of systemic lupus erythematosus. Arth. Rheum. 25:1982;1271-1277.
55. Theofilopoulos A. N., Dixon F. J. Etiopathogenesis of murine SLE. Immunol. Rev. 55:1981;179-216.
56. Verthelyi D., Ahmed S. A. 17β-estradiol, but not 5-α-dihydrotestosterone, augments antibodies to double-stranded deoxyribonucleic acid in non-autoimmune C57BL/6J mice. Endocrinology. 135:1994;2615-2622.
57. Waters N. S., Badura L. L., Ahmed S. A., Gogal R. M., Denenberg V. H. Manipulation of behavioral disorders in autoimmune mice via prolactin. Physiol. Behav. 62:1997;983-988.
58. Watts R. H. A simple capillary tube method for the determination of the specific gravity of 25 μl and 50 μl quantities of urine. J. Clin. Pathol. 24:1971;667-668.
59. Weinberger S. B., Schulteis G., Fernando A. G., Bakhit C., Martinez J. L. Decreased locomotor activity produced by repeated, but not single, administration of murine-recombinant interferon-gamma in mice. Life Sci. 42:1988;1085-1090.